The resulting increased stabilization of ErbB2 by p130Cas might be the crucial event driving breast cancer progression and resistance, strengthening the relevance of p130Cas as an unfavorable prognostic marker and a putative therapeutic target to overcome resistance to trastuzumab based treatment in ErbB2 positive breast cancers. The gene discussed is BCAR1; the disease is breast carcinoma.